Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

(2018) Jorge A. Marrero et al.   HEPATOLOGY

Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan

(2018) Terumi Kaishima et al.   HEPATOLOGY RESEARCH

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations

(2017) Takeru Shiroiwa et al.   HEALTH POLICY

Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation

(2017) Franco Trevisani et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology

(2016) Breda H. Eubank et al.   BMC Medical Research Methodology

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

(2016) Shuichi Kaneko et al.   JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

(2016) Masatoshi Kudo et al.   JOURNAL OF GASTROENTEROLOGY

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

(2015) Phil McEwan et al.   HEPATOLOGY RESEARCH

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

(2015) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

(2015) Calin Cainap et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

(2015) Robert J Motzer et al.   LANCET ONCOLOGY

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of interventional radiology in the management of hepatocellular carcinoma

(2014) N. Molla et al.   Current Oncology

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

(2013) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region

(2013) Mi Na Kim et al.   JOURNAL OF GASTROENTEROLOGY

Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6

(2012) Andrew H. Briggs et al.   VALUE IN HEALTH

Elicitation of health state utilities in metastatic renal cell carcinoma

(2010) Paul Swinburn et al.   CURRENT MEDICAL RESEARCH AND OPINION

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

(2009) Takeru Shiroiwa et al.   HEALTH ECONOMICS

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE